MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ctro.2025.101035

Медицинская библиотека · Clinical and translational radiation oncology · 2025

Neoadjuvant prostate artery embolization prior to prostate radiation therapy: A single institution experience on the durability of clinical urinary improvement after radiation.

Khatri Vaseem M, Grass G Daniel, Thapa Ram, Maun-Garcia Laura, Latifi Kujtim, Naghavi Arash O, Garg Aditya, Fernandez Daniel, Torres-Roca Javier, Rishi Anupam, Jazayeri-Moghaddas Omeed, Pow-Sang Julio, Johnstone Peter A S, Yamoah Kosj, Parikh Nainesh

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Radiation therapy (RT) for prostate cancer has gastrointestinal and genitourinary toxicities, greater with baseline lower urinary tract symptoms (LUTS) and larger prostate volume (PV). Prostate artery embolization (PAE) improves LUTS and PV before RT. This study evaluates the durability of LUTS improvement from neoadjuvant PAE before prostate RT and oncologic outcomes.

METHODS

We retrospectively identified patients receiving definitive prostate RT following PAE from a prospective database, including International Prostate Symptom Scores (IPSS), pre- and post-PAE MRI PV, and toxicity per CTCAEv5.0. Primary objective was LUTS by IPSS. Secondary objectives included biochemical recurrence-free survival (bRFS), local recurrence, and distant metastasis.

RESULTS

From 9/2017-5/2024, 82 patients underwent PAE before RT, with 30.5 % having unfavorable intermediate risk. RT consisted of conventional fractionation (n = 21), moderate hypofractionation (n = 42), SBRT (n = 11), and EBRT/brachytherapy boost (n = 8); a subset of patients received androgen deprivation therapy. Pelvic lymph nodes were treated in 28 (34 %) patients. Median pre-PAE IPSS was 18 (range 2-34), PV 90 cc (14.2-240), and PSA 8.4 ng/mL (0.02-125.5). Post-PAE, mean IPSS reduction was 10.7 points (-13-30). Mean PV reduction was 30.9 cc (-9-136) or 32 %. PAE converted 52 % of patients contraindicated by size/IPSS for brachytherapy/SBRT. Post-RT, mean IPSS changes at 3, 6, 12, 18 and 24 months were -8.7, -8.5, -9.5, -8.9, and -7.6, respectively (p < 0.001). At 24.2-month median follow-up, 1 local recurrence occurred. Two-year bRFS was 92 % for non-metastatic patients.

CONCLUSION

Urinary improvement is durable after RT in men with large prostates and/or high LUTS burden with neoadjuvant PAE, and no increased risk of recurrence at intermediate-term follow-up. Further investigation is warranted.

Для цитирования: Khatri Vaseem M, Grass G Daniel, Thapa Ram, Maun-Garcia Laura, Latifi Kujtim, Naghavi Arash O, Garg Aditya, Fernandez Daniel, Torres-Roca Javier, Rishi Anupam, Jazayeri-Moghaddas Omeed, Pow-Sang Julio, Johnstone Peter A S, Yamoah Kosj, Parikh Nainesh. Neoadjuvant prostate artery embolization prior to prostate radiation therapy: A single institution experience on the durability of clinical urinary improvement after radiation.. Clinical and translational radiation oncology. 2025. DOI: 10.1016/j.ctro.2025.101035.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.